Progress in pharmacotherapy for Alzheimer's disease
In recent years,with the development of disease-modifying therapies(DMT)such as monoclonal antibodies against amyloid-beta protein(Aβ),drug treatment for Alzheimer's disease(AD)has entered a new era.Currently,two antibodies targeting Aβ—aducanumab and lecanemab—have been approved for clinical use,attracting widespread attention worldwide.Meanwhile,remark-able progress has also been made in the development of drugs against non-Aβ and non-tau targets.This review highlights the latest ad-vances in the development and application of drugs for AD that have been clinically approved or in clinical trials.
Alzheimer's diseasepharmacotherapyanti-amyloid-beta monoclonal antibodysigma receptor-targeting drug
万方数据
维普
